Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$765.21 USD

765.21
1,129,785

-3.79 (-0.49%)

Updated Aug 5, 2025 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?

by Kinjel Shah

Investors may stay invested in PFE stock to see how its new growth drivers perform.

Zacks Equity Research

Company News for May 2, 2025

by Zacks Equity Research

Companies In The News Are: CVS, LLY, CAH, ICE.

Zacks Equity Research

LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down

by Zacks Equity Research

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates. Stock declines.

Zacks Equity Research

Initial Claims More Than Expectations

by Zacks Equity Research

Initial Claims More Than Expectations.

Zacks Equity Research

Here's What Key Metrics Tell Us About Lilly (LLY) Q1 Earnings

by Zacks Equity Research

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Eli Lilly (LLY) Q1 Earnings Lag Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of -5.11% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Shaun Pruitt headshot

Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?

by Shaun Pruitt

Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.

Shaun Pruitt headshot

Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?

by Shaun Pruitt

Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.

Zacks Equity Research

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

by Zacks Equity Research

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Ahan Chakraborty headshot

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

by Ahan Chakraborty

NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.

Zacks Equity Research

Pfizer (PFE) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron

by Zacks Equity Research

Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Zacks Equity Research

Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?

by Zacks Equity Research

Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.

Kinjel Shah headshot

Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)

by Kinjel Shah

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Zacks Equity Research

Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Kinjel Shah headshot

Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PFE vs. LLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

by Zacks Equity Research

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Ahan Chakraborty headshot

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

by Ahan Chakraborty

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

Zacks Equity Research

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?

by Kinjel Shah

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.